Abstract
Introduction
Exposing rodents to brief episodes of hypoxia mimics the hypoxemia and the cardiovascular and metabolic effects observed in patients with sleep-disordered breathing (SDB) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . SDB includes different respiratory disorders -the most frequent being obstructive sleep apnoea (OSA) and hypoapnoea. OSA corresponds to recurrent episodes of complete or partial pharyngeal collapse during sleep resulting in intermittent hypoxia (IH) and sleep fragmentation [1, [12] [13] [14] [15] [16] [17] [18] .
OSA affects between 5% and 20% of the population and apart from daytime sleepiness, is associated with high incidence of hypertension, peripheral vascular disease, stroke and sudden cardiac death [7, 19] . However, the mechanisms by which OSA and cardiovascular disease are linked remain obscure since patient studies are complicated by the confounding effects of disease duration and the many comorbidities present in OSA patients.
The first animal study showing that IH induces hypertension was reported by Fletcher, et al. [20] . They exposed rats to IH (3-5% nadir ambient oxygen) every 30 sec., 7 hrs per day for up to 35 days and demonstrated a significant increase in mean arterial blood pressure (MAP) over baseline of 13.7 Ϯ 1.8 mmHg [20] . Follow-up studies have confirmed these observations despite multiple differences in the exposure paradigms, pCO2 levels, species and strains of animals [1, 5, [21] [22] [23] [24] [25] [26] [27] [28] [29] . In addition, some of these elegant studies have demonstrated elevations of arterial blood pressure that persist after termination of the intermittent hypoxic exposure. Therefore, it is now established that systemic hypertension [20] , dyslipidemia [30] and early atherosclerosis (14) as well as vascular remodelling [5, 20] 
Mechanisms of IH-induced systemic hypertension

Contribution of the nervous system
It has been well established that IH-induced elevation in blood pressure involves enhanced sympathetic nerve activity [33] [34] [35] [36] [37] [38] , increased adrenal catecholamine secretion [39] [40] [41] [42] , decreased baroreflex [28, 43] and enhanced chemoreflex sensitivity [5, 19, 21, 36, 44, 45] [84] [85] [86] [87] . In addition, ROS increases ET-1 mRNA and peptide levels in endothelial, smooth muscle and CB (glomus) cells [88, 89] sensitization [90] .
Contribution of circulating and vascular factors
ROS can also increase angiotensinogen synthesis contributing to the activation of the renin-angiotensin system (RAS) [91, 92] . Interestingly, Ang II by increasing ROS production leads to upregulation of ET-1 [93, 94] . Therefore, ROS has not only been implicated as activator of these systems but also as part of the signalling downstream of both ET-1 [95] and Ang II [93, [96] [97] [98] [99, 100] . However other studies have shown no changes in the components of RAS in patients [101] [102] [103] and that administration of an Ang II receptor inhibitor (losartan) does not prevent IH-induced hypertension in rats [37] .
Although it may not be acting as a pressor agent, elevated plasma levels of Ang II in OSA patients appears to contribute to increases in plasma levels of vascular endothelial growth factor (VEGF) [100, 104] . VEGF is a potent angiogenic cytokine that also contributes to atherogenesis. Therefore, it is possible that Ang II through VEGF contributes to angiogenesis, endothelium repair and atherosclerosis more than to hypertension in OSA. [106] ).
Role of transcription factors in the inflammatory and cardiovascular consequences of IH
Increases in inflammatory factors have been associated with induction of vascular damage and hypertension. Three transcription factors -NF-B, NFAT and HIF-1-have been implicated in the initiation of the inflammatory response and the associated vascular damage induced by IH.
NF-B The NF-B is a key mediator of the inflammatory response under many conditions. NF-B is a member of the Rel family of proteins and was first described as a nuclear factor necessary for immunoglobulin k light chain transcription in B-cells [105]. NF-B exists in the cytosol in an inactive form bound to the inhibitor, IB. An appropriate endogenous or exogenous inflammatory stimulus triggers IB ubiquitin-mediated degradation releasing NF-B to translocate to the nucleus. In the nucleus, NF-B up-regulates the transcription of several pro-inflammatory genes responsible for encoding inflammatory cytokines (tumour necrosis factor [TNF]-␣, interleukin [IL]-6 and IL-8), chemokines, surface adhesion molecules (intercellular adhesion molecule-1) and enzymes (cyclooxygenase-2) (reviewed in
There is evidence suggesting IH increases NF-B activity and its downstream products, particularly TNF-␣ in cultured cell, animal models and OSA patients. TNF-␣ has been shown to play a major role in inflammation-mediated vascular damage in OSA patients and animal models (reviewed in [107]).
Cultured HeLa cells (an epithelial cell line) and bovine aortic endothelial cells exposed to IH show activation of NF-B [108] . IH activation of NF-B is dependent on IB kinase and p38 MAPK activity [109] .
The same group also demonstrated increases in TNF-␣ and the NF-B-dependent cytokine, IL-8 in plasma of OSA patients [108, 110] . In mice, IH increased the expression of NF-B -dependent gene product, iNOS, in cardiovascular tissues (heart, aorta and lung) of mice [111] . Finally, OSA patients have significantly elevated monocyte and neutrophil NF-B activity, which was normalized following elimination of apnoeas with continues positive airway pressure (CPAP) therapy [111, 112] .
Interestingly, NF-B is a redox-sensitive transcription factor [113, 114] [115] [115, 116] ). NFAT binds DNA with very low affinity in the absence of a cofactor so that formation of an NFAT-cofactor-DNA ternary complex is required for significant NFAT-mediated transcriptional activity. Egr-1 [117, 118] , activator protein 1 (AP-1) [119, 120] , YY1 [121] , the MADS family member -MEF2 [122] [123] [124] and members of the GATA family [125, 126] (reviewed in [127] ) have been shown to be NFAT cofactors.
that can initiate inflammatory and immune responses by promoting activation of endothelial cells, leucocytes and platelets. These activated cells express adhesion molecules and pro-inflammatory cytokines that may contribute to endothelial injury and dysfunction and consequently to the development of cardio-and cerebro-vascular morbidities in IH.
NFAT
Another member of the Rel family of transcription factors that has recently been implicated in the development of hypertension in IH exposed mice is the nuclear factor of activated T cells (NFAT) (Fig. 2) [29]. First identified in activated T cells, the calcium (Ca 2ϩ )-dependent transcription factor, NFAT, has since been shown to play a role in non-immune cells, including cells of the cardiovascular system (reviewed in
NFAT activation is generally associated with an increase in gene expression [116, 127] . However, several reports have shown that NFAT can also function as a repressor of gene expression [128] [129] [130] [131] .
Activators of Gq-couple receptors (i.e. ET-1, Ang II, catecholamines, uridine 5Ј-triphosphate), elevated plasma glucose levels and increased intravascular pressure are potent activators of NFAT [115, [132] [133] [134] [135] [136] . NFAT activation not only plays an important role in modulating the immune response and inflammation [116] , it is also important in vascular development [137, 138] , maintenance of the contractile phenotype of vascular smooth muscle cells (VSMC) [126, 139, 140] [128, 131, 141] .
and regulation of VSMC contractility through the down-regulation of voltage-dependent (KV 2.1) channel and large conductance (BK) potassium channels
Smooth muscle-specific expression of NFAT isoforms has been described. NFATc1 and NFATc2 were the first reported in thoracic aortic smooth muscle cells from rat [142] . More recently human aortic smooth muscle was shown to express NFATc1 and c3, but not NFATc2 or c4 [126] . Extensive studies of the cerebral vasculature reveal NFATc3 and c4, but not NFATc1 or c2 [132] [133] [134] [135] [152] . OPN plasma levels are increased in hypertension [153, 154] , coronary artery disease [155] and by hypoxia [156] . [157] [158] [159] . In models of systemic inflammatory response, OPN levels have been found to directly correlate with secretion of IL-6 [160] . Interestingly, ROS also enhance expression of OPN in VSMC [161, 162] .
OPN expression is induced by a variety of growth factors and cytokines including IL-1, TNF-␣ and Ang II
ROS also activate NFAT in many different cell types including neuronal-like cells, immune cells, osteoclasts and cardiac myocytes [77] [78] [79] [80] [81] [82] . The mechanism by which ROS activates NFAT has not been completely established but, in cardiomyocytes, H2O2 induces a time-and dose-dependent activation of NFAT [81] . This activation appears to be mediated by ERK- 
HIF-1
Hypoxia-inducible factor (HIF)-1 is a heterodimeric transcription factor formed by a constitutively expressed ␤-subunit and an ␣-subunit that contains an oxygen-dependent ubiquitin-proteasomal degradation domain [163, 164] oxygen consumption [166] . One of the first genes shown to be regulated by HIF-1 was erythropoietin (EPO) whose gene promoter contains hypoxia response elements. Up-regulation of EPO leads to increased red blood cell production and enhanced blood oxygen-carrying capacity [167] . Studies from our group have shown that IH without CO2 supplementation (hypocapnia) increases haematocrit in rats [168] . However, IH with CO2 supplementation (eucapnia) does not increase haematocrit in either rats [168] [170] .
Another HIF-1 gene product is VEGF, which it has been demonstrated to be elevated in OSA patients with severe nocturnal hypoxemia [171] . VEGF induces migration of mature endothelial cells towards hypoxic areas of tissue, thereby promoting angiogenesis [172] . IH increases HIF-1 in endothelial cells in culture [173, 174] 
This was accompanied by an increase in myocardial pre-pro ET-1 levels, ET-1 protein and ET-A receptor expression and by enhanced coronary vascular reactivity to ET-1 in SHR only. Myocardial HIF-1 activity was also increased and in vivo chromatin immunoprecipitation assay on myocardial extracts provided evidence that HIF-1␣ targets the ET-1 gene in SHR after IH. Moreover, administration of bosentan, a mixed ET receptor antagonist, during IH prevented both the increase in blood pressure and in infarct size. This study demonstrates that activation of the ET system, mediated by HIF-1 activity, is responsible for the enhanced susceptibility to IH and for its associated cardiovascular consequences leading to hypertension and ischemic injury.
Yuan G, et al. have investigated the molecular mechanism of HIF-1␣ up-regulation during IH [179]. The mechanism includes both increased mTOR-dependent HIF-1␣ synthesis during re-oxygenation and decreased hydroxylase-dependent HIF-1␣ degradation during hypoxia. HIF-1␣ up-regulation also appears to require increased generation of ROS by NOX. Anti-oxidants prevented IH decreased hydroxylation of HIF-1␣ protein. Ca 2ϩ -dependent activation of phospholipase C␥ and PKC are also required for decreased HIF-1␣ degradation.
There [187, 188] . OSA additionally exacerbates pulmonary hypertension in patients with COPD (a condition termed 'overlap syndrome'), and CPAP is effective in reducing the severity of pulmonary hypertension in these individuals [189, 190] . However, whether OSA directly causes sustained daytime pulmonary hypertension in the absence of co-existing chronic lung disease or obesity-related hypoventilation is debated. Interestingly, recent studies suggest that OSA is an independent risk factor in PH [187, [191] [192] [193] , with an incidence of approximately 20-40% in patients without clinically identifiable cardiopulmonary disease [187, [190] [191] [192] [193] [194] [195] [196] [197] . Supporting this finding is evidence that CPAP reduces daytime pulmonary arterial pressure in pulmonary hypertensive OSA patients without significant heart disease, lung disease [191] [192] [193] or daytime hypoxemia [191, 192] . This relationship between OSA and PH has been reviewed extensively elsewhere [187, 189, 190, 198] [27, 168, [199] [200] [201] [202] (Fig. 3) . The degree of pulmonary hypertension closely correlates with right ventricular hypertrophy [203] , an adaptive response to the increase in afterload. Although clinical manifestations of right heart failure and peripheral oedema resulting from severe PH can develop in patients with overlap syndrome, such complications are uncommon in individuals with OSA uncomplicated by concomitant lung disease [187, [190] [191] [192] [193] [194] [195] [196] [197] .
is also an active NF-B binding site in the proximal promoter site of the HIF-1 gene and NF-B appears to regulate basal levels of HIF-1 gene expression [180]. Indeed, hypoxia up-regulation of HIF-1 transcription appears to be through a NF-B-dependent mechanism and vice versa [180-182]. Interestingly these studies further established a role for ROS as a factor that contributes to the significant crosstalk between NF-B and HIF-1, suggesting mutual dependence between the pathways. The O2 regulated ␣ subunit of HIF-2␣, also known as endothelial PAS domain protein-1, is another member of the HIF family [183]. HIF-2␣ shares 80% sequence homology to HIF-1␣ and also interacts with HIF-1␤ [184]. Similar to HIF-1, continuous hypoxia leads to HIF-2␣ accumulation and the resulting transcriptional activation of VEGF [185]. In contrast to the up-regulation of HIF-1␣, it has been shown that IH down-regulates HIF-2␣ protein levels via activation of calpain proteases [186]. IH-evoked HIF-2␣ degradation led to inhibition of SOD2 transcription, resulting in greater oxidative stress. Systemic administration of calpain inhibitors restored HIF-2␣ levels in IH-exposed rats and prevented IH-induced oxidative stress and cardiovascular abnormalities. Together these studies suggest that IH activates HIF-2␣ leading to increases in ROS, which act in concert with the low O2 levels to up-regulate HIF-1 and contribute to IH-induced hypertension.
Intermittent hypoxia induced pulmonary hypertension
Pulmonary hypertension (PH) is an additional cardiovascular complication of OSA. Patients with OSA demonstrate cyclical increases in pulmonary arterial pressure coinciding with apnoeic episodes, which has been largely attributed to acute hypoxic pulmonary vasoconstriction (HPV)
. Mechanisms of IH-induced PH are generally considered to be parallel to those associated with chronic sustained hypoxia (CH), and include pulmonary vasoconstriction, vascular remodelling (characterized by smooth muscle hypertrophy and hyperplasia in small pulmonary arteries) and polycythemia
Whether CH and IH produce PH through similar mechanisms is not clear, but studies comparing the two models suggest that the PH resulting from IH is less severe. For example, Fagan [200] [204, 205] . Recent studies from our group and others suggest that the vasoconstrictor response to sustained CH may be multifaceted, with contributions of both spontaneous pulmonary arterial tone [206] and enhanced agonist-dependent vasoconstriction [168, 207, 208] . Whereas IH also enhances pulmonary vasoreactivity to the thromboxane mimetic, U-46619, the magnitude of this response is markedly blunted compared to that observed with CH [168] . [205-207, 209, 210] . [168] , preliminary studies from our group indicate that IH similarly augments VSM reactivity to ET-1 in pressurized small pulmonary arteries from rats through a PKC signalling pathway [214] . Interestingly, this mechanism of increased PKC-dependent vasoconstriction following IH stands in marked contrast to our findings of enhanced kinase-mediated myofilament Ca 2ϩ sensitivity in the pulmonary circulation of CH rats [207] . [222, 223] have been the major sources of ROS implicated in the development of pulmonary hypertension. Indeed, a role for NOX in IH-dependent PH has recently been reported by Nisbet and colleagues [201] , who found that the NOX subunits NOX4 and p22phox and ROS levels are increased in lungs from IH mice (1.3 
Additional research is needed to define the contribution of vasoconstriction to IH-induced pulmonary hypertension, and whether increased vasoreactivity in this setting is the result of altered VSM signal transduction or endothelial dysfunction, both of which occur following CH
Previous studies from our group have identified ET-1 as a critical mediator of IH-induced systemic hypertension in rats [23, 68] (discussed above). Given the well established contribution of ET-1 to CH-induced PH [211-213], that circulating ET-1 levels are elevated in IH rats [23], and pre-pro ET-1 mRNA is up-regulated in lungs from IH mice [29] a distinct possibility is that ET-1 similarly contributes to IH-induced PH. Future studies are needed to assess the potential role of ET-1 in this response, and potential influences of ET-1 on the remodelling and vasoconstrictor responses to IH. In agreement with evidence that IH augments pulmonary vasoconstrictor sensitivity to U-46619
Whether such increases in pulmonary vasoconstrictor sensitivity to ET-1 contribute to IH-dependent PH remains to be established. Considering the contribution of ROS to IH-induced systemic hypertension [63], and the well-established role of ROS in various models of hypoxic PH [215-217], a reasonable hypothesis is that
ROS similarly contribute to the development of IH-induced pulmonary hypertension. NOX [215, 218-221] and xanthine oxidase
min. cycles of 10%/21% O2, 8 hrs/day, 5 days/ week, 8 weeks). Evidence from this same study that IH-induced RV hypertrophy and arterial remodelling are abolished in NOX2 (gp91phox) knockout mice further supports a major contribution of NOX2-derived ROS in this pulmonary hypertensive response.
The mechanisms by which ROS mediate IH-dependent pulmonary hypertension are not understood, but may involve both enhanced pulmonary vasoconstrictor sensitivity [207, 214] and increases in gene expression secondary to activation of HIF-1 [179] . Consistent with the latter possibility and as reviewed above, studies using HIF-1␣ heterozygous mice suggest that HIF-1-mediated gene expression is central to not only the development of CHinduced PH [224] , but to CB-mediated ROS generation and associated cardiorespiratory responses to IH as well [45] . Whether a functional link exists between NOX, HIF-1 activity and vasoconstrictor sensitivity in the development of IH-induced pulmonary hypertension remains to be determined.
Apnoeic episodes in patients with SDB are associated not only with hypoxemia but with hypercapnia as well [225] . Therefore, studies that employ a purely IH stimulus without provision of supplemental CO2 do not accurately reflect the blood gas changes that occur during apnoeic episodes in OSA patients. Rather, the hypoxic increases in ventilation resulting from IH alone lead to cyclical reductions in arterial Pco2 and consequent alkalemia [168] . To more closely mimic the arterial blood gas and pH changes observed in patients with sleep apnoea, studies in our group have begun to compare effects of IH with and without supplemental CO2 on indices of pulmonary hypertension, polycythemia and pulmonary vasoreactivity. Interestingly, we found that supplemental CO2 significantly reduces the arterial remodelling, polycythemic and right ventricular hypertrophic responses to IH [168] . These results are consistent with earlier studies demonstrating a protective influence of CO2 on the development of CH-induced pulmonary hypertension [226, 227] . Although the mechanisms by which CO2 reduces the severity of PH are not understood, it is possible that supplemental CO2 leads to suppression of oxidant stress [227] (Fig. 4) , which contribute to inflammation, endothelial dysfunction, vascular remodelling and increased vasoconstriction leading to hypertension. 
In addition, important new questions have been raised regarding the mechanisms that mediate both vasoconstrictor and arterial remodelling components of IH-dependent PH, including the roles of ET-1, ROS, PKC and HIF-1-induced gene expression. Neither is it understood how CO2 blunts the pulmonary hypertensive response to IH, nor whether a similar protective influence of CO2 exists in human beings. Animal models of PH will continue to improve our understanding of potential differences in the pathogenesis of CH versus IH-induced PH, which in turn is necessary to indentify effective therapeutic strategies to treat these conditions.
Conclusions
Rodent models of IH have provided a tremendous advance in our understanding of the cardiovascular alterations observed in patients with SDB. After reviewing the literature on this field is clear that ROS plays a major role in the pathogenesis of the cardiovascular morbidities induced by IH and also present in SDB patients. We are proposing a working model where ROS is the activator of the main factors enhanced by IH but also is part of the intracellular signalling pathways initiated by these factors
